-
公开(公告)号：US10457719B2
公开(公告)日：2019-10-29
申请号：US12678494
申请日：2008-09-17
摘要： In certain embodiments, this present invention provides antibodies and Fc fusion proteins with enhanced pharmacokinetics, such as biotinylated antibodies or biotinylated Fc fusion polypeptides.
-
2.发明申请ANTIBODIES AND FC FUSION PROTEIN MODIFICATIONS WITH ENHANCED PERSISTENCE OR PHARMACOKINETIC STABILITY IN VIVO AND METHODS OF USE THEREOF 审中-公开抗生素和FC融合蛋白修饰，其具有增强的持久性或药物动力学稳定性及其使用方法公开(公告)号：US20100209424A1
公开(公告)日：2010-08-19
申请号：US12678494
申请日：2008-09-17
IPC分类号： A61K39/395 , C07K16/00
CPC分类号： C07K16/00 , A61K47/557 , A61K47/6835 , A61K2039/505 , C07K2317/21 , C07K2317/24 , C07K2317/72 , Y02A50/396
摘要： In certain embodiments, this present invention provides antibodies and Fc fusion proteins with enhanced pharmacokinetics, such as biotinylated antibodies or biotinylated Fc fusion polypeptides.
摘要翻译： 在某些实施方案中，本发明提供具有增强的药代动力学的抗体和Fc融合蛋白，例如生物素化的抗体或生物素化的Fc融合多肽。
-
公开(公告)号：US20060129331A1
公开(公告)日：2006-06-15
申请号：US11341699
申请日：2006-01-26
申请人： Shreeram Akilesh , Kevin Mills , Derry Roopenian , Daniel Shaffer
发明人： Shreeram Akilesh , Kevin Mills , Derry Roopenian , Daniel Shaffer
摘要： Systems and methods for performing rapid genomic DNA analysis of samples, such as control samples and experimental samples. In one aspect, the system makes use of genomic DNA input, rather than gene expression input such as mRNA and/or cDNA associated with mRNA. The systems and methods perform statistical analyses on data generated from the samples to determine which DNA sequences in an identified set of DNA sequences have a basis of variation in an experimental sample when compared to a control sample, and additionally provide a quantitative measure of this variation. The quantitative measure may be based on metrics such as copy number and/or fold-change. The systems and methods employ this statistical framework in DNA-based evaluation settings, including the evaluation/diagnosis of a pathological condition such as cancer or transgenic analysis of transgenic plants and animals. The systems and methods also provide means to select and refine the selection of DNA sequences, such as genes, known to undergo copy change for a particular pathological condition. This leads to the creation of stock gene sets catered to individual application areas and/or clinical uses, which may be used with the systems and methods described in this application for the purpose of, for example, a clinical kit for rapid DNA-based evaluation.
摘要翻译： 用于进行样品快速基因组DNA分析的系统和方法，如对照样品和实验样品。 在一个方面，该系统利用基因组DNA输入，而不是基因表达输入，例如与mRNA相关的mRNA和/或cDNA相关的基因表达输入。 系统和方法对从样本产生的数据执行统计分析，以确定当与对照样品相比时，确定的DNA序列集合中的哪些DNA序列具有实验样品的变化基础，并另外提供该变化的定量测量 。 定量测量可以基于诸如拷贝数和/或折叠变化之类的度量。 系统和方法在基于DNA的评估设置中采用这种统计框架，包括病理条件如癌症或转基因植物和动物的转基因分析的评估/诊断。 系统和方法还提供了选择和改进DNA序列选择的方法，例如已知对特定病理状况进行复制变化的基因。 这导致创建适合于个体应用领域和/或临床应用的库存基因组，其可以与本申请中描述的系统和方法一起使用，用于例如用于快速基于DNA的评估的临床试剂盒 。
-
公开(公告)号：US20100023272A1
公开(公告)日：2010-01-28
申请号：US12511493
申请日：2009-07-29
摘要： Methods and applications of Global Patter Recognition (GPR), including a system for analyzing the results of real-time polymerase chain reaction (RT-PCR) experiments employing micro-titer and/or microarray plates and robotic plate readers is described. The system employs a set of self-normalizing housekeeping primers or oligonucleotides on the plates/arrays and an algorithmic approach to normalizing expression data from all primers on the plate based on the reaction products of several of the self-normalizing gene primers oligonucleotides. Normalization is accomplished using simplex reactions involving these self-normalizing primers/oligonucleotides; the normalization parameters are then useable across all control and experimental reactions of the plate/array. A ranked list of genes whose amount of change is statistically significant can be determined. The accuracy of this list is enhanced by the data normalization aspect of the system. Other applications of GPR are also disclosed herein.
摘要翻译： 描述了全球散射识别（GPR）的方法和应用，包括用于分析使用微滴度和/或微阵列板和机器人读板器的实时聚合酶链反应（RT-PCR）实验的结果的系统。 该系统在板/阵列上采用一套自标准化管家引物或寡核苷酸，以及基于几个自归一化基因引物寡核苷酸的反应产物，从板上所有引物标准化表达数据的算法方法。 使用涉及这些自标准化引物/寡核苷酸的单纯形反应来实现标准化; 标准化参数随后可用于板/阵列的所有控制和实验反应。 可以确定其变化量具有统计学显着性的基因的排名列表。 该列表的准确性由系统的数据归一化方面增强。 本文还公开了GPR的其它应用。
-
公开(公告)号：US06992234B2
公开(公告)日：2006-01-31
申请号：US09993322
申请日：2001-11-06
申请人： Derry Roopenian
发明人： Derry Roopenian
CPC分类号： C12N15/8509 , A01K67/0276 , A01K67/0278 , A01K2207/15 , A01K2217/00 , A01K2217/075 , A01K2227/105 , A01K2267/01 , A01K2267/0325 , A61K2039/505 , C07K14/70535
摘要： Disclosed is a transgenic knockout mouse whose genome comprises a homozygous disruption in its endogenous FcRn gene. The homozygous FcRn disruption prevents the expression of a functional FcRn protein, resulting in a transgenic knockout mouse in which exogenously administered IgG1 exhibits a substantially shorter half-life, as compared to the half-life of exogenously administered IgG1 in a wild-type mouse. The transgenic knockout mouse with a homozygous FcRn disruption is also unable to absorb maternal IgG in the prenatal or neonatal stage of development. Also disclosed is a transgenic knockout mouse comprising a homozygous FcRn disruption and a human FcRn transgenic. The transgenic addition of human FcRn results in a substantial increase in the half-life of exogenously administered human IgG1. Methods of using the transgenic knockout mouse, and cells derived from them, are also disclosed.
摘要翻译： 公开了一种转基因敲除小鼠，其基因组包含其内源FcRn基因的纯合破坏。 与野生型小鼠中外源性施用的IgG1的半衰期相比，纯合的FcRn破坏阻止功能性FcRn蛋白的表达，导致转基因敲除小鼠，其中外源施用的IgG1表现出明显较短的半衰期。 具有纯合FcRn破坏的转基因敲除小鼠在产前或新生儿发育阶段也不能吸收母体IgG。 还公开了包含纯合FcRn破坏和人FcRn转基因的转基因敲除小鼠。 人FcRn的转基因添加导致外源性施用的人IgG1的半衰期显着增加。 还公开了使用转基因敲除小鼠的方法和从它们衍生的细胞。
-
公开(公告)号：US20080166338A1
公开(公告)日：2008-07-10
申请号：US11958540
申请日：2007-12-18
申请人： Warren J. Leonard , Katsutoshi Ozaki , Rosanne Spolski , Herbert C. Morse , Peter E. Lipsky , Derry Roopenian
发明人： Warren J. Leonard , Katsutoshi Ozaki , Rosanne Spolski , Herbert C. Morse , Peter E. Lipsky , Derry Roopenian
IPC分类号： A61K39/395 , A61P43/00
CPC分类号： C07K14/7155 , A01K67/0276 , A01K2217/05 , A01K2227/105 , A01K2267/0381 , C07K14/5406 , C12N15/8509
摘要： A transgenic mouse is disclosed herein whose somatic and germ cells comprise a disrupted IL-21 receptor gene, the disruption being sufficient to inhibit the binding of IL-21 to an IL-21 receptor, and a disrupted IL-4 gene, the disruption being sufficient to inhibit the production of IL-4 or the binding of IL-4 to the IL-4 receptor. A mouse homozygous for the disrupted IL-21 receptor gene and homozygous for the disrupted IL-4 gene has diminished B cell function. A method is disclosed for altering a B cell activity. The method includes administering a therapeutically effective amount of an agent that interferes with the interaction of IL-21 with an IL-21 receptor, thereby altering the B cell activity. A method is also disclosed for of treating a subject with Job's disorder or atopic disease. A method is also disclosed for treating or preventing an allergic reaction in a subject. A method is also disclosed for treating a subject with an autoimmune or antibody mediated disorder.
摘要翻译： 本文公开了一种转基因小鼠，其体细胞和生殖细胞包含破坏的IL-21受体基因，所述破坏足以抑制IL-21与IL-21受体的结合以及破坏的IL-4基因，所述破坏是 足以抑制IL-4的产生或IL-4与IL-4受体的结合。 对于破坏的IL-21受体基因纯合的小鼠和破坏的IL-4基因是纯合的，具有减少的B细胞功能。 公开了用于改变B细胞活性的方法。 该方法包括施用治疗有效量的干扰IL-21与IL-21受体相互作用的试剂，由此改变B细胞活性。 还公开了用于治疗患有约瑟病或特应性疾病的受试者的方法。 还公开了用于治疗或预防受试者的过敏反应的方法。 还公开了用自身免疫或抗体介导的病症治疗受试者的方法。
-
公开(公告)号：US20060031954A1
公开(公告)日：2006-02-09
申请号：US11235996
申请日：2005-09-27
申请人： Derry Roopenian
发明人： Derry Roopenian
IPC分类号： A01K67/027
CPC分类号： C12N15/8509 , A01K67/0276 , A01K67/0278 , A01K2207/15 , A01K2217/00 , A01K2217/075 , A01K2227/105 , A01K2267/01 , A01K2267/0325 , A61K2039/505 , C07K14/70535
摘要： Disclosed is a transgenic knockout mouse whose genome comprises a homozygous disruption in its endogenous FcRn gene. The homozygous FcRn disruption prevents the expression of a functional FcRn protein, resulting in a transgenic knockout mouse in which exogenously administered IgG1 exhibits a substantially shorter half-life, as compared to the half-life of exogenously administered IgG1 in a wild-type mouse. The transgenic knockout mouse with a homozygous FcRn disruption is also unable to absorb maternal IgG in the prenatal or neonatal stage of development. Also disclosed is a transgenic knockout mouse comprising a homozygous FcRn disruption and a human FcRn transgene. The transgenic addition of human FcRn results in a substantial increase in the half-life of exogenously administered human IgG1. Methods of using the transgenic knockout mouse, and cells derived from them, are also disclosed.
摘要翻译： 公开了一种转基因敲除小鼠，其基因组包含其内源FcRn基因的纯合破坏。 与野生型小鼠中外源性施用的IgG1的半衰期相比，纯合的FcRn破坏阻止功能性FcRn蛋白的表达，导致转基因敲除小鼠，其中外源施用的IgG1表现出明显较短的半衰期。 具有纯合FcRn破坏的转基因敲除小鼠在产前或新生儿发育阶段也不能吸收母体IgG。 还公开了包含纯合FcRn破坏和人FcRn转基因的转基因敲除小鼠。 人FcRn的转基因添加导致外源性施用的人IgG1的半衰期显着增加。 还公开了使用转基因敲除小鼠的方法和从它们衍生的细胞。
-
公开(公告)号：US20050193434A1
公开(公告)日：2005-09-01
申请号：US11027868
申请日：2004-12-30
申请人： Warren Leonard , Katsutoshi Ozaki , Rosanne Spolski , Herbert Morse , Peter Lipsky , Derry Roopenian
发明人： Warren Leonard , Katsutoshi Ozaki , Rosanne Spolski , Herbert Morse , Peter Lipsky , Derry Roopenian
IPC分类号： A01K67/027 , C07K14/54 , C07K14/715 , C12N20060101 , C12N15/85 , C12Q1/68 , G01N33/53
CPC分类号： C07K14/7155 , A01K67/0276 , A01K2217/05 , A01K2227/105 , A01K2267/0381 , C07K14/5406 , C12N15/8509
摘要： A transgenic mouse is disclosed herein whose somatic and germ cells comprise a disrupted IL-21 receptor gene, the disruption being sufficient to inhibit the binding of IL-21 to an IL-21 receptor, and a disrupted IL-4 gene, the disruption being sufficient to inhibit the production of IL-4 or the binding of IL-4 to the IL-4 receptor. A mouse homozygous for the disrupted IL-21 receptor gene and homozygous for the disrupted IL-4 gene has diminished B cell function. A method is disclosed for altering a B cell activity. The method includes administering a therapeutically effective amount of an agent that interferes with the interaction of IL-21 with an IL-21 receptor, thereby altering the B cell activity. A method is also disclosed for of treating a subject with Job's disorder or atopic disease. A method is also disclosed for treating or preventing an allergic reaction in a subject. A method is also disclosed for treating a subject with an autoimmune or antibody mediated disorder.
摘要翻译： 本文公开了一种转基因小鼠，其体细胞和生殖细胞包含破坏的IL-21受体基因，所述破坏足以抑制IL-21与IL-21受体的结合以及破坏的IL-4基因，所述破坏是 足以抑制IL-4的产生或IL-4与IL-4受体的结合。 对于破坏的IL-21受体基因纯合的小鼠和破坏的IL-4基因是纯合的，具有减少的B细胞功能。 公开了用于改变B细胞活性的方法。 该方法包括施用治疗有效量的干扰IL-21与IL-21受体相互作用的试剂，由此改变B细胞活性。 还公开了用于治疗患有约瑟病或特应性疾病的受试者的方法。 还公开了用于治疗或预防受试者的过敏反应的方法。 还公开了用自身免疫或抗体介导的病症治疗受试者的方法。
-
公开(公告)号：US07822556B2
公开(公告)日：2010-10-26
申请号：US12511493
申请日：2009-07-29
IPC分类号： G01N33/50
摘要： Methods and applications of Global Patter Recognition (GPR), including a system for analyzing the results of real-time polymerase chain reaction (RT-PCR) experiments employing micro-titer and/or microarray plates and robotic plate readers is described. The system employs a set of self-normalizing housekeeping primers or oligonucleotides on the plates/arrays and an algorithmic approach to normalizing expression data from all primers on the plate based on the reaction products of several of the self-normalizing gene primers oligonucleotides. Normalization is accomplished using simplex reactions involving these self-normalizing primers/oligonucleotides; the normalization parameters are then useable across all control and experimental reactions of the plate/array. A ranked list of genes whose amount of change is statistically significant can be determined. The accuracy of this list is enhanced by the data normalization aspect of the system. Other applications of GPR are also disclosed herein.
摘要翻译： 描述了全球散射识别（GPR）的方法和应用，包括用于分析使用微滴度和/或微阵列板和机器人读板器的实时聚合酶链反应（RT-PCR）实验的结果的系统。 该系统在板/阵列上采用一套自标准化管家引物或寡核苷酸，以及基于几个自归一化基因引物寡核苷酸的反应产物，从板上所有引物标准化表达数据的算法方法。 使用涉及这些自标准化引物/寡核苷酸的单纯形反应来实现标准化; 标准化参数随后可用于板/阵列的所有控制和实验反应。 可以确定其变化量具有统计学显着性的基因的排名列表。 该列表的准确性由系统的数据归一化方面增强。 本文还公开了GPR的其它应用。
-
公开(公告)号：US07358416B2
公开(公告)日：2008-04-15
申请号：US11235996
申请日：2005-09-27
申请人： Derry Roopenian
发明人： Derry Roopenian
IPC分类号： A01K67/00
CPC分类号： C12N15/8509 , A01K67/0276 , A01K67/0278 , A01K2207/15 , A01K2217/00 , A01K2217/075 , A01K2227/105 , A01K2267/01 , A01K2267/0325 , A61K2039/505 , C07K14/70535
摘要： Disclosed is a transgenic knockout mouse whose genome comprises a homozygous disruption in its endogenous FcRn gene. The homozygous RcRn disruption prevents the expression of a functional FcRn protein, resulting in a transgenic knockout mouse in which exogenously administered IgG1 exhibits a substantially shorter half-life, as compared to the half-life of exogenously administered IgG1 in a wild-type mouse. The transgenic knockout mouse with a homozygous RcRn disruption is also unable to absorb maternal IgG in the prenatal or neonatal stage of development. Also disclosed is a transgenic knockout mouse comprising a homozygous FcRn disruption and a human FcRn transgene. The transgenic addition of human FcRn results in a substantial increase in the half-life of exogenously administered human IgG1. Methods of using the transgenic knockout mouse, and cells derived from them, are also disclosed.
摘要翻译： 公开了一种转基因敲除小鼠，其基因组包含其内源FcRn基因的纯合破坏。 与野生型小鼠中外源性施用的IgG1的半衰期相比，纯合的RcRn破坏阻止功能性FcRn蛋白的表达，导致转基因敲除小鼠，其中外源施用的IgG1表现出显着更短的半衰期。 具有纯合RcRn破坏的转基因敲除小鼠也不能在产前或新生儿发育阶段吸收母体IgG。 还公开了包含纯合FcRn破坏和人FcRn转基因的转基因敲除小鼠。 人FcRn的转基因添加导致外源性施用的人IgG1的半衰期显着增加。 还公开了使用转基因敲除小鼠的方法和从它们衍生的细胞。
-
-
-
-
-
-
-
-
-
搜索结果
10 条记录 (耗时 0.028 秒)
